The molecular basis of islet amyloid induced beta-cell death and the inhibition of islet amyloid induced toxicity (360G-Wellcome-107927_Z_15_Z)

£1,732,599

Amyloid formation plays a central role in a wide range of devastating diseases, but the mechanism of amyloid formation has yet to be defined in detail for any protein. The nature of the toxic species produced during amyloid formation is controversial and efforts at drug development have been disappointing. This proposal exploits new approaches, developed in our laboratory, to address these critical issues. Our work is focused on islet amyloidosis by the neuropancreatic hormone islet amyloid polypeptide (IAPP, also known as Amylin) and its role in type-2 diabetes (T2D) and beta cell death. Key questions are: (1) What is the mechanism of IAPP amyloid formation?(2) What are the properties of the toxic oligomers produced during islet amyloidosis? (3) What distinguishes toxic from non-toxic oligomers and what factors correlate with toxicity? (4) Why do some amyloid inhibitors protect against toxicity while other promote it? Answering these questions is central to an understanding of amyloidosis and to developing effective therapeutic strategies.

Where is this data from?

This data was originally published by The Wellcome Trust. If you see something about your organisation or the funding it has received on this page that doesn't look right you can submit a grantee amendment request. You can hover over codes from standard codelists to see the user-friendly name provided by 360Giving.

Grant Details

Amount Awarded 1732599
Applicant Surname Raleigh
Approval Committee Science Interview Panel
Award Date 2015-07-07T00:00:00+00:00
Financial Year 2014/15
Grant Programme: Title Investigator Award in Science
Internal ID 107927/Z/15/Z
Lead Applicant Prof Daniel Raleigh
Partnership Value 1732599
Planned Dates: End Date 2024-02-21T00:00:00+00:00
Planned Dates: Start Date 2017-02-21T00:00:00+00:00
Recipient Org: Country United Kingdom
Region Greater London